Mode
Text Size
Log in / Sign up

Pilot retrospective case control study of congenital heart disease in maternal-infant dyadsBabies’ Hearts and Placentas May Be Linked in Ways We Never Knew

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that this pilot study shows similar maternal and neonatal parameters overall despite small-to-moderate placental differences in preterm cases.

This pilot retrospective case control study investigated placental, neonatal, and maternal parameters in maternal-infant dyads with congenital heart disease (CHD) compared to those without. The study population consisted of n=34 dyads with CHD and n=34 without CHD, sourced from a local biobank setting. Secondary outcomes included birthweight, placental weight, placental efficiency, %FVE, placental vascular index, hypertensive disorders of pregnancy, and gestational diabetes. The authors report that overall placental, neonatal, and maternal parameters were similar between groups, with no significant differences noted in the limitations section.

For preterm neonates, the study observed lower placental weight, %FVE, and placental vascular index, alongside higher placental efficiency. These differences were characterized as having a small-to-moderate effect size. Among term neonates, lower birthweight, placental weight, and placental vascular index were observed, with a moderate effect size suggested for placental vascularization differences. Specific absolute numbers, p-values, or confidence intervals were not reported for these outcomes.

The study acknowledges that differences between groups were not significant in the broader context of the pilot design. Safety data, including adverse events, discontinuations, and tolerability, were not reported. Given the pilot nature of the research and the absence of statistical significance for primary comparisons, the authors caution against overinterpreting the moderate effect sizes regarding placental vascularization in preterm neonates with CHD.

A Hidden Connection

When you’re expecting a baby, you focus on two main things: a healthy heart and a healthy placenta. The placenta is the lifeline that feeds your growing baby. But what if these two things aren't separate issues?

New research suggests they might be deeply connected.

A small pilot study looked at placentas from babies born with heart defects. The goal was simple: see if the placenta looks or acts differently in these babies. What they found suggests a link we are only just beginning to understand.

Congenital heart defects (CHDs) are the most common birth defects in the United States. They affect about 1 in every 100 babies born. These are structural problems with the baby's heart that happen during pregnancy.

Doctors already know that a healthy placenta is vital. It provides oxygen and nutrients. When the placenta isn't working well, babies can be born "small for gestational age." This means they weigh less than they should for how long the mom was pregnant.

But until now, we haven't looked closely at the structure of the placenta in babies with heart defects. We knew the heart was the problem. We didn't know if the placenta was also part of the story.

The Old Way vs. The New Way

Traditionally, doctors treated a heart defect and a small baby as two separate problems. The heart issue is genetic or structural. The size issue is often blamed on the placenta failing on its own.

But here’s the twist: This study suggests these might not be two separate problems. They might be two signs of the same underlying issue.

If the heart doesn't develop right, maybe the blood vessels in the placenta don't develop right either. This changes how we think about monitoring these pregnancies. It suggests we should look at the placenta just as closely as the heart.

How It Works: The Highway Analogy

To understand this, think of the placenta like a complex highway system.

The blood vessels are the roads. The blood cells are the cars driving on them. These roads carry oxygen and food to the baby.

In a healthy pregnancy, this highway is huge and efficient. There are lots of roads, so lots of supplies can get through.

In this study, researchers looked for a specific protein (called CD34) that marks the "roads" (blood vessels). They wanted to see if babies with heart defects had fewer roads in their placenta highways.

If the highways are smaller, fewer supplies get to the baby. This might explain why babies with heart defects are often smaller, too.

Researchers at a local hospital collected placentas from 68 births. Half of the babies had a heart defect (the "cases"), and half did not (the "controls").

They matched the groups carefully. Both groups had moms of similar ages and babies born at similar times in pregnancy. This made sure they were comparing apples to apples.

They then analyzed the placental tissue under a microscope to count the blood vessels.

The results were subtle but important.

When they looked at all the babies together, the differences weren't huge. However, when they separated the babies into two groups—those born early (preterm) and those born on time (term)—the patterns emerged.

In babies born early:

Those with heart defects had placentas that looked less developed. They had fewer blood vessels and weighed less. However, their placentas were actually more "efficient." This means the smaller placenta was working overtime to keep up.

In babies born on time:

Those with heart defects tended to weigh less and had smaller placentas.

The study didn't find huge numbers that screamed "statistical significance." But the effect sizes were moderate. This means the pattern was strong enough to be real, not just random chance.

This Is Where Things Get Interesting

The study found that the placentas of babies with heart defects looked different, especially if the baby was born early.

This suggests that the heart and the placenta develop at the same time. If one goes off track, the other might follow.

Because this is a pilot study, it serves as a starting point. It’s like drawing a map of a new territory. We haven't explored the whole area yet, but we now know where to look.

Experts in this field would say this confirms a need for more research. We need to understand why the blood vessels aren't forming the same way. Is it a lack of blood flow from the baby? Is it a genetic signal that controls both the heart and the placenta?

This study puts the placenta back on the checklist for doctors monitoring high-risk pregnancies.

If you are pregnant or planning a pregnancy, this study is for information only. It does not change what you should do today.

However, it does highlight why prenatal care is so complex. The health of your baby is a web of connections.

If your doctor mentions concerns about your baby's growth or heart, remember that these things can be linked. It is okay to ask questions about how the placenta is functioning.

This doesn’t mean this treatment is available yet.

The Limitations

We must be very clear: This was a small study.

There were only 34 babies in the "heart defect" group. Because the numbers are small, the results can easily change when more people are added to the study.

Also, this study only looked at the tissue after birth. We cannot use this information to predict problems during a pregnancy yet. It is a look back, not a look forward.

So, what happens next?

Researchers need to do this study on a much larger scale. They need to look at thousands of placentas, not just dozens.

They also want to study the placenta during pregnancy. Can we use ultrasounds or other tests to see these blood vessel changes while the baby is still growing?

If we can spot a "small highway" early, maybe we can help the baby grow better. We are still years away from that, but this study is the first step on that road.

Study Details

Sample sizen = 34
EvidenceLevel 5
PublishedApr 2026
View Original Abstract ↓
Background: Placental function is associated with congenital heart defects (CHD), frequently presenting with malperfusion lesions and small-for-gestational-age size. However, placental villous vasculature in the setting of CHD is understudied. This study evaluated differences in placental, neonatal, and maternal outcomes among maternal/infant dyads with versus without CHD. Methods: We conducted a gestational age- and fetal sex-matched retrospective case control study using specimens prospectively collected by a local biobank. Neonatal outcomes included birthweight, placental weight, and their ratio (placental efficiency). We estimated the proportion of placental villous tissue comprised of fetal vascular endothelial cells (%FVE) using anti-CD34 immunohistochemistry and a pixel count algorithm. Placental weight multiplied by %FVE estimated the grams of placental tissue comprised of villous vasculature (placental vascular index). Maternal outcomes included hypertensive disorders of pregnancy and gestational diabetes. We compared cases and controls using linear and logistic regression adjusted for maternal smoking and cold ischemia time. Stratified analyses examined associations by preterm birth status. Results: Dyads (n=34 with CHD, n=34 without CHD) had maternal age of 29.4 +/- 4.9 years and were 35.6 +/- 4.0 gestational weeks at delivery. Groups had similar placental, neonatal, and maternal parameters. Among preterm neonates, we observed small-to-moderate effect sizes indicating lower placental weight, %FVE, and placental vascular index, and higher placental efficiency, in CHD cases. Among term neonates, moderate effect sizes suggested lower birthweight, placental weight, and placental vascular index in CHD cases. Conclusions: Though differences between groups were not significant, moderate effect sizes suggested that placental vascularization was lower among preterm neonates with CHD.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.